Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Multi-Center, Open Label, Dose Escalation Study to Determine the RP2D, Safety and Efficacy of GSK2857916 in Combination With Pomalidomide and Low-Dose Dexamethasone in Subjects With Relapsed and/or Refractory Multiple Myeloma

NCT03715478 is registered in ClinicalTrials.gov with Canadian Myeloma Research Group as lead sponsor.

NCT NCT03715478
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03715478 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Multi-Center, Open Label, Dose Escalation Study to Determine the RP2D, Safety and Efficacy of GSK2857916 in Combination With Pomalidomide and Low-Dose Dexamethasone in Subjects With Relapsed and/or Refractory Multiple Myeloma
Lead sponsor
Canadian Myeloma Research Group
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
November 26, 2018
Completion date
December 31, 2026
Enrollment
120 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed and/or refractory multiple myeloma